Renewal of Contract

Hikma Pharmaceuticals Plc 22 November 2006 Hikma Pharmaceuticals PLC Renewal of Contract London, 22 November 2006 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) announces the renewal of the sales contract with the Department of Veterans Affairs, an agency of the government of the United States of America, for the supply of lisinopril. The renewal represents the exercise of the 4th Option Year for the contract with a contract period between 21 December 2006 and 20 December 2007. The contract has been renewed at a slight discount to last year's renewal price. All other terms and conditions of the contract remain unchanged. - ENDS - Enquiries: Hikma Pharmaceuticals PLC +44 20 7399 2670 Susan Ringdal, Investor Relations Director Brunswick Group LLP +44 20 7404 5959 Jon Coles / Justine McIlroy / Alex Tweed Notes to Editors About Hikma Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: Generic, Branded and Injectable Pharmaceuticals. Hikma's operations are based principally in the United States, the Middle East and North Africa ('MENA') region and Europe. In 2005, the Group had revenue of $262 million and profit attributable to shareholders of $44 million. At 31 December 2005, the Group had over 1,800 employees. For news and other information, please visit www.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange